Adjuvant zoledronic acid for breast cancer: mechanism of action?

被引：10
|
作者：
Kunzmann, Volker [1 ,2 ]
Wilhelm, Martin [3 ]
机构：
[1] Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany
[3] Klinikum Nurnberg, Clin Med Oncol & Hematol, Nurnberg, Germany
来源：
LANCET ONCOLOGY | 2011年 / 12卷 / 11期
关键词：
IN-VIVO; THERAPY; WOMEN;
D O I：
10.1016/S1470-2045(11)70252-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：991 / 992
页数：4
相关论文
共 50 条
  • [21] Uveitis, a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer
    Chacko, Geena
    Kota, Srigowri
    Kumar, Shicha
    Ohri, Nisha
    Omene, Coral
    Ganesan, Shridar
    Toppmeyer, Deborah L.
    George, Mridula A.
    ANTI-CANCER DRUGS, 2023, 34 (04) : 592 - 594
  • [22] Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer
    Gallo, M.
    De Luca, A.
    Lamura, L.
    Normanno, N.
    ANNALS OF ONCOLOGY, 2012, 23 (03) : 597 - +
  • [23] Zoledronic acid in the treatment of metastatic breast cancer
    Lluch, Ana
    Cueva, Juan
    Ruiz-Borrego, Manuel
    Ponce, Jose
    Perez-Fidalgo, Jose-Alejandro
    ANTI-CANCER DRUGS, 2014, 25 (01) : 1 - 7
  • [24] Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study
    Wilson, C.
    Bell, R.
    Hinsley, S.
    Marshall, H.
    Brown, J.
    Cameron, D.
    Dodwell, D.
    Coleman, R.
    EUROPEAN JOURNAL OF CANCER, 2018, 94 : 70 - 78
  • [25] Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis
    Wen-Bin Zhou
    Peng-Ling Zhang
    Xiao-An Liu
    Tao Yang
    Wei He
    Journal of Experimental & Clinical Cancer Research, 30
  • [26] Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer
    Andrew P. Jallouk
    Sriram Paravastu
    Katherine Weilbaecher
    Rebecca L. Aft
    Breast Cancer Research and Treatment, 2021, 187 : 135 - 144
  • [27] Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis
    Zhou, Wen-Bin
    Zhang, Peng-Ling
    Liu, Xiao-An
    Yang, Tao
    He, Wei
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2011, 30
  • [28] Skeletal effects of adjuvant zoledronic acid and its cessation in women with early-stage breast cancer
    Ramchand, Sabashini K.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 (09) : 1203 - 1204
  • [29] Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer
    Jallouk, Andrew P.
    Paravastu, Sriram
    Weilbaecher, Katherine
    Aft, Rebecca L.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (01) : 135 - 144
  • [30] Should adjuvant zoledronic acid be used in early-stage, endocrine-sensitive breast cancer?
    Lamond, Nathan William Dana
    Skedgel, Chris
    Rayson, Daniel
    Younis, Tallal
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345